nav atļauts
nav atļauts
Digitālo tiesību pārvaldība (Digital Rights Management (DRM))
Izdevējs ir piegādājis šo grāmatu šifrētā veidā, kas nozīmē, ka jums ir jāinstalē bezmaksas programmatūra, lai to atbloķētu un lasītu. Lai lasītu šo e-grāmatu, jums ir jāizveido Adobe ID. Vairāk informācijas šeit. E-grāmatu var lasīt un lejupielādēt līdz 6 ierīcēm (vienam lietotājam ar vienu un to pašu Adobe ID).
Nepieciešamā programmatūra
Lai lasītu šo e-grāmatu mobilajā ierīcē (tālrunī vai planšetdatorā), jums būs jāinstalē šī bezmaksas lietotne: PocketBook Reader (iOS / Android)
Lai lejupielādētu un lasītu šo e-grāmatu datorā vai Mac datorā, jums ir nepieciešamid Adobe Digital Editions (šī ir bezmaksas lietotne, kas īpaši izstrādāta e-grāmatām. Tā nav tas pats, kas Adobe Reader, kas, iespējams, jau ir jūsu datorā.)
Jūs nevarat lasīt šo e-grāmatu, izmantojot Amazon Kindle.
Chapter 1: Introduction to Pharmacovigilance: Ensuring Medication Safety.
Chapter 2: Drug Safety Signal Detection and management in Pharmacovigilance.Chapter 3: Databases and Tools for Signal Detection of Drugs in Post-Marketing Surveillance.Chapter 4: Role of Electronic medical records, Social Media, Claims data, distributed data networks in signal analysis.Chapter 5: Uncovering False Alarms: Examining Biases and Confounders in Disproportionality Analysis.Chapter 6: Role of Medical Coding in Signal Detection.
Chapter 7: Regulatory Aspects in Signal Detection and Assessment.
Chapter 8: Disproportionality Methods for Signal Detection in Pharmacovigilance.
Chapter 9: Bayesian methods of signal detection.
Chapter 10: Subgroup and sensitivity analysis.
Chapter 11: Causality Assessment of ICSRs.
Chapter 12: Signal Analysis of Drug-Drug Interaction Using Spontaneous Reporting Method.
Chapter 13: Use of network pharmacological approaches in signal analysis.
Chapter 14: Docking studies in signal analysis: An overview.
Chapter 15: Molecular Dynamics simulations in signal validation.
Chapter 16: Identification and validation of novel signal of drugs using FAERS database: A case study.
Chapter 17: Molecular docking and molecular dynamics in Signal analysis: A case study.
Chapter 18: Available Databases and Tools for signal detection of vaccines.
Chapter 19: Identification and validation of signals associated with vaccines.Chapter 20: Neurological and behaviour alterations with COVID-19 vaccines using Vaccine Adverse Event Reporting System (VAERS): A Retrospective study.
Chapter 21: Pharmacovigilance based drug repurposing via inverse signals.Chapter 22: Prospective role of preclinical experimentation in validating the safety signals.Chapter 23: Role of Artificial Intelligence in Signal Detection.
24. Index.